Thrombin: Difference between revisions
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
(38 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
<StructureSection load='1ppb' size='350' side='right' scene='' caption='Human thrombin large (red) and small (green) subunits complex with prolinamide derivative (PDB code [[1ppb]])'> | |||
__TOC__ | |||
==Introduction== | |||
'''Thrombin''' (Thr) is a serine protease. '''Prothrombin''' (PThr) is cleaved by prothrombinase at 2 cleavage sites to form the 2 chains of Thr in the coagulation cascade<ref>PMID:23809130</ref>. The first step of the cleavage is at residue R320 and produces '''meizothrombin''' (MThr)<ref>PMID:22815477</ref>. Thr catalyzes the conversion of fibrinogen to the insoluble fibrin. Thr is composed of heavy chain (HC) and light chain (LC). '''Prethrombin-1''' lacks 155 N-terminal residues of PThr and is composed of a single polypeptide chain. '''Prethrombin-2''' is the product of proteolysis of '''prethrombin-1''' by trypsin or by active factor X. P-PACK Thr is a chemically modified Thr with inactivated catalytic site and active anion binding site. [[Hirudin]] is the most potent natural inhibitor of Thr ([[Sean Swale/Human Thrombin Inhibitor]]). For some more details see [[Serine Proteases]]. Prothrombin cleavage results in the creation of thrombin, a coagulative agent in plasma and is connected to fibrinolysis and platelet activation. During this process several peptides involved in the conversion are released into the plasma, and the remaining protein splits into two portions(http://www.uniprot.org/citations/3759958). It has been shown that prothrombin has a statistically significant connection to the occurrence of ischemic stroke with the presence of the G20210A mutation, though the cause was not isolated to prothrombin alone (http://www.uniprot.org/citations/15534175) (these links added by Connor Gramazio). Some additional details in<br /> | |||
* [[Ann Taylor 115]]<br /> | |||
* [[Sean Swale/Human Thrombin Inhibitor]]<br /> | |||
* [[Thrombin heavy chain]]<br /> | |||
* [[Thrombin light chain]]<br /> | |||
* [[Thrombin (hebrew)]]<br /> | |||
'' | <scene name='58/583418/Thombin_main_secondary/2'>Thrombin</scene> catalyzes the penultimate step in blood coagulation. It is activated from its [http://en.wikipedia.org/wiki/Zymogen zymogen], prothrombin, at the site of tissue injury by [[Factor_Xa | Factor Xa (FXa)]] and its cofactor [http://en.wikipedia.org/wiki/Factor_V FVa] in the presence of phospholipid membrane and calcium. Thrombin is then able to catalyze the cleavage of [[Fibrinogen | fibrinogen]] to insoluble fibrin which spontaneously polymerizes to form a stable clot.<ref name="zero">PMID: 7023326</ref><ref name="one">PMID: 11001069</ref> Thrombin also acts as a procoagulant by: | ||
* Activating platelets through their [http://en.wikipedia.org/wiki/Protease-activated_receptor protease activated receptors (PARs)]<ref name="one"/> | |||
* Preventing [http://en.wikipedia.org/wiki/Von_Willebrand_factor Von Willebrand factor (VWF)] processing by cleaving [http://en.wikipedia.org/wiki/ADAMTS13 ADAMTS13] <ref name="two">PMID: 15388580</ref><ref name="three">PMID: 15994286</ref> | |||
* Enhancing its own production through [[Factor_XI | FXI]] activation <ref name="three"/> | |||
* Activating the fibrin crosslinking transglutaminase [[Factor_XIII | FXIII]] <ref>PMID: 4811064</ref> | |||
* Activation of [http://www.ncbi.nlm.nih.gov/pubmed/17008302 thrombin activatable fibrinolysis inhibitor (TAFI)] <ref>PMID: 20229688</ref> | |||
== | Activity of thrombin is regulated physiologically by the [http://en.wikipedia.org/wiki/Serpin serpin inhibitors]: | ||
* [[Antithrombin]] <ref name="three"/><ref name='four'>PMID: 24477356</ref><ref name='five'>PMID: 23809129</ref> | |||
* [http://en.wikipedia.org/wiki/Heparin_cofactor_II Heparin cofactor II]<ref name="three"/><ref name='four'/><ref name='five'/> | |||
* [http://en.wikipedia.org/wiki/Protein_C_inhibitor Protein C inhibitor]<ref name="three"/><ref name='four'/><ref name='five'/> | |||
* [http://www.sciencedirect.com/science/article/pii/0968000484900744 Protease nexin 1]<ref name="three"/><ref name='four'/><ref name='five'/> | |||
Generation of thrombin is decreased when thrombin reaches endothelial lining and interacts with [[1fge |thrombomodulin]] which significantly increases activity of thrombin in activating [http://en.wikipedia.org/wiki/Protein_C protein C (PC -> APC)].<ref>PMID: 3029867</ref> This enzyme will go on to inactivate FVa<ref>PMID: 7989361</ref><ref name='six'>PMID: 8639840</ref> and [[Factor_VIII | FVIIIa]]<ref name='six'/> , cofactors for activation of prothrombin<ref>PMID: 15147718</ref> and [[Factor_Xa | FXa]]<ref>PMID: 10881749</ref>, respectively. | |||
By balancing substrate specificity, activity, and inhibition thrombin plays a central role in the blood coagulation cascade. <ref name="three"/> | |||
[[Image:Substrates.png|450px|center|thumb| Coagulation related substrates of thrombin, excluding serpin inhibitors.]] | |||
{{Clear}} | |||
==The Thrombin Life Cycle== | |||
Upon tissue damage [http://en.wikipedia.org/wiki/Tissue_factor tissue factor (TF)] is released by subendothelial cells. This interacts with circulating [[Factor_VII| FVIIa]], a zymogen-like serine protease, significantly increasing its activity. '''The FVIIa-TF complex (extrinsic Xase) activates FVII, FIX, and FX'''. The now active '''FXa cleaves prothrombin''' bound to membranes through its [http://en.wikipedia.org/wiki/Gla_domain gamma-carboxyglutamyl (Gla) domain], activating it to thrombin. | |||
Thrombin interacts with platelet membrane protein [http://www.ncbi.nlm.nih.gov/pubmed/14720584 GpIbα] and subsequently '''cleaves protease activated receptor-1 (PAR1)''' causing a signaling cascade which leads to platelet [http://en.wikipedia.org/wiki/Platelet_alpha-granule α-granule] release and membrane flipping exposing the negatively charged [http://en.wikipedia.org/wiki/Phosphatidylserine phosphatidylserine]. The platelet alpha granules contain the physiologically relevant pool of FVa. <ref>Camire, R. M. (2010). Platelet factor V to the rescue. Blood, 115(4), 753-754. [http://bloodjournal.hematologylibrary.org/content/115/4/753.full DOI: 10.1182/blood-2009-11-252619]</ref> | |||
Thrombin also causes activation of FIX, through [http://en.wikipedia.org/wiki/Factor_XI FXI] cleavage, and FVIII which form the Xase complex to activate FX. '''FVa and FXa form the [http://en.wikipedia.org/wiki/Prothrombinase prothrombinase] complex''' in the presence of calcium and phospholipid. It causes rapid activation of prothrombin to thrombin. This increase in thrombin allows sufficient fibrinogen to be cleaved to fibrin which is able to polymerize to form a stable [http://en.wikipedia.org/wiki/Thrombus blood clot]. | |||
Further supporting coagulation, '''thrombin activates FXIII''', a [http://en.wikipedia.org/wiki/Transglutaminase transglutaminase] that crosslinks fibrin at lysine residues. | |||
The structure of thrombin facilitates its inactivation. Once the endothelial lining is reached '''thrombin binds [http://en.wikipedia.org/wiki/Heparin heparin] or related [http://en.wikipedia.org/wiki/Glycosaminoglycan glycosaminoglycans]'''. This facilitates its inactivation by serpin inhibitors antithrombin and heparin cofactor II. In addition, '''thrombin will interact with [http://en.wikipedia.org/wiki/Thrombomodulin thrombomodulin]''' which significantly increases its catalytic efficiency activating protein C. '''Activated protein C inactivates FVIIa and FVa''' thus down regulating thrombin generation. | |||
Thrombin plays a critical dual role in blood coagulation. It must be both promiscuous and specific so that it may complete both procoagulant and anticoagulant functions. The structure of thrombin facilitates its important physiologic functions. | |||
==Prothrombin Activation== | |||
[[Image:Prothrombin activation scheme_3.png|450px|left|thumb| Activation scheme of in vivo activation of prothrombin by FXa in the absence of FVa.]] | |||
{{Clear}} | |||
[[Image:Prothrombin activation scheme_nofva3.png|450px|left|thumb| Activation scheme of in vivo activation of prothrombin by the prothrombinase complex in presence of calcium and a phospholipid bilayer]] | |||
{{Clear}} | |||
Prothrombin is the zymogen form of thrombin. From N-terminal to C-terminal it consists of a Gla domain, two kringle domains, and a catalytic domain. The Gla domain is formed by vitamin K dependent carboxylation of glutamate residues.<ref>PMID: 18374193</ref> | |||
'''Prothrombin is activated by prothrombinase''' which consists of FXa, FVa, calcium, and a phospholipid surface. In vivo the first cleavage occurs at the R320-I321 bond, corresponding to residues 15-16 in chymotrypsin which is the N-terminus of the B chain, producing meizothrombin.<ref name='seven'>PMID: 22944689</ref> Subsequent cleavage at R271-T272 yields thrombin.<ref name='seven'/> The initial cleavage can also occur at R271 resulting in prethrombin-2 which will then be cleaved at R320 to produce thrombin.<ref>PMID: 1995649</ref> | |||
After cleavage by prothrombinase the new B chain '''N-terminus (Ile16) folds into the core protease domain''' and forms a salt bridge with Asp194.<ref name='seven'/> This leads to stabilization of regions of the 180s-loop, Na+ binding loop, and γ-loop (zymogen activation domains). These changes provide the '''correct conformation for the S1 pocket and oxyanion hole for catalysis'''.<ref name='seven'/><ref>PMID: 15890651</ref> | |||
==Structure and Function== | |||
[[Image:Electrostatic labeled.png|450px|right|thumb| Thrombin (1PPB) overlayed with electrostatic surface. Structural features 60-loop, γ-loop, exosite I, and exosite II labeled]] | |||
{{Clear}} | |||
Thrombin is a α/β heterodimer composed of a 36 amino acid A chain and 259 amino acid B chain connected by a <scene name='58/583418/Disulfides_nospin/1'>disufide</scene> bridge between Cys1 and Cys122, in addition to 3 other intrachain disulfide bonds.<ref name='eight'>PMID: 2583108</ref> Its overall fold is similar to trypsin and chymotrypsin and it belongs to the [http://merops.sanger.ac.uk/cgi-bin/famsum?family=s1 peptidase S1 protease family]<ref>PMID: 18768474</ref>. It is an overall spherical protein with approximate dimensions of 45 Å X 45 Å X 50 Å.<ref name='eight'/> | |||
Important structural features include: | |||
* A prominent active site cleft flanked by the 60- and γ-loops | |||
* A sodium binding loop | |||
* Two surface patches referred to as exosite I and exosite II. | |||
The <scene name='58/583418/A_chain_nospin/1' target='0'>A chain</scene> is mostly helical and is wound around the B chain and shaped like a boomerang. It is bound to the B chain mostly through side chain interactions including a salt bridge and a hydrogen bond cluster at residues D14, E8, and E14c.<ref name='eight'/> Furthermore the C-terminus region forms a short amphipathic helix with hydrophobic side chains interacting with the B chain.<ref name='eight'/> | |||
'' | The <scene name='58/583418/B_chain/1'>B chain</scene> contains the active site of the protein and has numerous notable structural features. The active site is formed at the rims of two interacting 6 stranded <scene name='58/583418/Beta_barrel/2'>beta barrel domains</scene>(N-terminal barrel in red and C-terminal barrel in orange) which are surrounded by 4 helical regions and many turns. | ||
=== | The serine protease <scene name='58/583418/Catalytic_triad/1'>catalytic triad</scene> ([http://en.wikipedia.org/wiki/Catalytic_triad wiki]) residues, based on chymotrypsin numbering, are Ser195, His57, and Asp102. As is common with serine proteases, an <scene name='58/583418/Oxyanion_hole/2'>oxyanion hole</scene> hole is formed by backbone amides of Ser195 and Gly193.<ref name='seven'/> This has the functional role of stabilizing the oxyanion intermediate involved in the serine protease mechanism by hydrogen bonding to the oxygen of the P1 residue (standard substrate-protease nomeclature <ref>PMID: 22925665</ref>. In addition, since thrombin cleaves after Arg/Lys the <scene name='58/583418/S1/3'>S1 specificity site</scene>, formed by the 180s- and 220s- loops, has Asp189 at the base to form a salt bridge with the incoming substrate. Furthermore, the S4 binding pocket accommodates hydrophobic substrate residues. | ||
The <scene name='58/583418/Loops/3'>active site</scene> cleft rims are formed by the hydrophobic and rigid <scene name='58/583418/Loops/3'>60-loop</scene> (residues L60, Y60a, P60b, P60c, W60d, D60e, K60f, N60g, F60h, T60i, and N60g) and the <scene name='58/583418/Loops/3'>γ-loop</scene> (residues T147, W147a, T147b, A147c, N147d, and V147f) while the base is mostly hydrophilic negatively charged amino acids. The cleft is deep compared to more promiscuous serine proteases, consequently substrates must either have a large loop that is cleaved or have favorable interactions with the insertion loops <ref>PMID: 16102053</ref>. | |||
Many other loops project out of the B chain but most are rigid due to proline and tryptophan residues. | |||
'''Exosite I''' is located on the B chain and had both basic and hydrophobic character. It is important in binding <scene name='58/583418/Fibrinogen/1'>fibrinogen</scene>, platelet activated receptors, and <scene name='58/583418/Thrombomodulin/1'>thrombomodulin</scene>. | |||
= | '''Exosite II''' is also part of the B chain, and derived from numerous basic amino acids, this is the site of <scene name='58/583418/Antithrombin/1'>heparin binding</scene> through the sulfate groups on the glycosaminoglycan. It is also the site of GpIbα binding on the platelet surface. | ||
The <scene name='58/583418/Sodium_binding_loop/1'>sodium binding site</scene> is formed by the 180s- and 220s- loops. Na+ is bound by the backbone oxygens of Arg221a and Lys224 in addition to four water molecules in a classic [http://chemwiki.ucdavis.edu/Inorganic_Chemistry/Crystal_Field_Theory/High_Spin_and_Low_Spin_Complexes#Octahedral_Geometry octahedral geometry]<ref>PMID: 9108691</ref>. Through the covelent disulfide linkage between Cys220 and Cys 191 the sodium binding site is linked to Ser195 and the oxyanion hole. | |||
'''Thrombin''' is a "trypsin-like" serine protease. Its structure (PDB code [[1ppb]]) is shown here with a peptide chloroketone inhibitor (PPACK). The thrombin A chain (cleaved N terminal fragement) is shown in cyan and the B chain is shown in red. The <scene name='Serine_Protease/Active_site/2'>Active site</scene> is made up of a catalytic triad of Ser195, His57 and Asp102, backed up by Ser214. The peptide chloroketone inhibitor (PPACK) is shown in purple. A closeup shows the <scene name='Serine_Protease/Activation_site/2'>activation site</scene> at which the sidechain of Asp194 makes a salt link with the N-terminus at residue 16, newly formed when the A chain is cleaved in the zymogen-to-enzyme activation process. The specificity pocket is on one side of the throat of the domain 2 beta barrel, and the activation site is close next to it. | |||
The B chain consists of <scene name='Serine_Protease/Domains/1'>two domains</scene>. As is true for all of the "trypsin-like" serine proteases, each of the two thrombin domains consists mainly of a 6-stranded, antiparallel beta barrel. The specificity pocket (here filled with the Lys sidechain of the PPACK inhibitor) is in one side of the throat of the domain 2beta barrel, and the activation site is close next to it. | |||
==Allostery== | |||
=== | Binding of thrombin by sodium or at exosite I stabilizes a form of thrombin that improves substrate recognition.<ref name='seven'/> This occurs due to energetic linkage between these sites to the S1 binding pocket and oxyanion hole. Rapid kinetic analysis suggests that '''thrombin is in a dynamic equilibrium that consists of a fast, slow, and inactive state'''<ref name='seven'/>. There is question as to the physiologic relevance of the inactive state. Regardless, there will be a proportion of fast:slow thrombin and sodium binding to the fast form stabilizes that conformation. Indeed, mutation of the residues involved in sodium binding diminishes the activity of thrombin.<ref name='seven'/> '''''It should be restated, current data suggest that sodium binding does not induce a conformation change, rather, it stabilizes a conformation of thrombin that has greater activity.''''' | ||
==Regulation and Inhibition== | |||
Thrombin is regulated by inhibition and down regulation of production. | |||
= | Antithrombin and heparin cofactor II are serpin inhibitors of thrombin that bind to specific sequences of sugar residues within a heparin chain on the endothelial lining.<ref>PMID: 15311269</ref> Thrombin also <scene name='58/583418/Antithrombin/1'>interacts with heparin</scene> nonspecific to sequence through its exosite II.<ref name='five'/> Thus, heparin acts as a surface that is outside of the procoagulant environment of the blood clot for thrombin interaction with inhibitors. | ||
= | <scene name='58/583418/Thrombomodulin/1'>Thrombomodulin</scene> also binds to heparin (through an [http://en.wikipedia.org/wiki/EGF-like_domain EGF-like domain]) and thombin, it causes a conformation in thrombin that increases activity for TAFI and protein C by 1000-fold.<ref>PMID: 24026641</ref> APC then inactivates FVa and FVIIIa effectively decreasing the concentration of prothrombinase and Xase respectively, and thereby down regulating thrombin production. | ||
Central to both of these regulation pathways are specific cofactor binding at thrombins exosites; thrombomodulin and antithrombin at exosite I and heparin at exosite II. Therefore the structure of thrombin uniquely provides it the functional properties necessary for regulation. | |||
==Secondary Structure Features== | |||
Thrombin has a <scene name='58/583418/Cis_proline/1'>cis peptide bond</scene> in a loop containing proline 37. The dihedral (C'-Cα-N-C') angle omega is -69.4 degrees. | |||
[[Image:Capping.png|450px|center|thumb| “Capping box” motif in alpha thrombin (PDB: 1PPB) represented by His230 (Ncap) side chain and main chain hydrogen bonded with the backbone nitrogen of Arg233 (N3). An additional feature is a weak hydrophobic interaction between Thr229 (N’) and Val234 (N4) termed the “hydrophobic staple.” This motif derives it’s name from the box shaped hydrogen bonding pattern.]] | |||
{{Clear}} | |||
[[Image:Cation pi.png|450px|center|thumb| A cation-π interaction between Trp128 and Arg 129 in alpha thrombin (PDB: 2BDY). The guanidinium carbon is 3.6 angstroms from the top edge of the Trp. It is expected that the epsilon nitrogen forms the primary cation-π interaction. The electrostatic and Van der Waals interaction energies were calculated to be -3.29 kcal/mol and -3.08 kcal/mol respectively by the CaPTURE program (http://capture.caltech.edu/result.cgi).]] | |||
{{Clear}} | |||
== 3D Structures of thrombin== | |||
[[Thrombin 3D Structures]] | |||
</StructureSection> | |||
== References == | |||
<references/> | |||
With participation by [[User:Cody Couperus]] | |||
[[Category:Topic Page]] | [[Category:Topic Page]] |